ArticleFrontiers in oncology2026
Chromosomal instability as a predictive biomarker for recurrence risk following transurethral resection of NMIBC.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate chromosomal instability (CIN) in tumor tissues from transurethral resection of bladder tumor (TURBT) and evaluate its feasibility as a molecular biomarker for prognostic stratification in non-muscle-invasive bladder cancer (NMIBC). Methods: In this retrospective single-center cohort study, DNA was extracted from formalin-fixed paraffin-embedded (FFPE) samples of 50 BC patients using the Qiagen nucleic acid extraction kit. The recurrence defined in this study refers to cystoscopically visible recurrence confirmed by biopsy or surgical pathology. All patients underwent follow-up until January 2025 in strict accordance with the protocol established by the EAU guidelines for NMIBC. Low-coverage whole-genome sequencing (LC-WGS) was performed to analyze CIN in bladder tumors. Time-dependent Receiver Operating Characteristic (ROC) analysis was performed to evaluate the predictive efficacy of CIN values for post-TURBT outcomes. Survival analysis was conducted using the Kaplan-Meier method (log-rank test), and associations between variables and recurrence-free survival (RFS) were assessed via Cox proportional hazards models. Results: Recurrent bladder cancer patients exhibited significant copy number alterations (CNAs) differences in 67 gene segments versus non-recurrent patients. Time-dependent ROC analysis demonstrates that CIN values exhibit good predictive performance between the 2nd and 5th years. High CIN was significantly associated with tumor recurrence, higher tumor grade, with high-CIN patients exhibiting poorer prognosis (median RFS: 22 months vs. unreached in the low-CIN group, p = 0.009). Multivariate analysis confirmed high CIN as an independent predictor of recurrence (HR = 5.22, 95% CI: 1.52-17.93, P = 0.009). Patients with single-chromosome copy number abnormalities also showed worse outcomes (median RFS: 16-23 months) compared to those without such abnormalities. No significant difference in RFS was detected between Ta and T1 stages (P = 0.577). Conclusion: High CIN exhibits a correlation with bladder tumor recurrence, higher tumor grade. High CIN or the presence of specific chromosomal abnormalities are indicative of an adverse prognosis. CIN may serve as a prognostic biomarker for predicting recurrence following TURBT, particularly between the 2nd and 5th years post-surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.